IN8bio, Inc. announced its financial results for Q4 and FY 2025, highlighting a 36% reduction in net loss and a strengthened balance sheet with $27.1 million in cash. The company reported significant survival improvements in glioblastoma treatments and closed a $20.1 million private placement.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.